



## **Synlogic to Webcast Presentation at BioCentury's 24th Annual NewsMakers in the Biotech Industry Conference**

September 1, 2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 1, 2017-- Synlogic (Nasdaq:SYBX) announced today that its chief medical officer, Aoife Brennan, M.B., B.Ch., will present a company overview at BioCentury's 24<sup>th</sup> Annual NewsMakers in the Biotech Industry Conference on Friday, September 8, 2017, at 10:00 a.m. ET, in New York City.

A live webcast of the presentation can be accessed under "Presentations" in the Investors & Media section of the Company's website at [www.synlogictx.com](http://www.synlogictx.com). An archived webcast recording will be available on the Synlogic website for approximately 30 days.

### **About Synlogic™**

Synlogic is pioneering the development of a novel class of living treatments, Synthetic Biotic™ medicines, based on its proprietary drug discovery and development platform. Synlogic's initial pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of more common diseases, including liver disease, inflammatory and immune disorders, and cancer. Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit [www.synlogictx.com](http://www.synlogictx.com).

View source version on businesswire.com: <http://www.businesswire.com/news/home/20170901005270/en/>

Source: Synlogic

### **Synlogic**

#### **INVESTOR CONTACT:**

Elizabeth Wolffe, Ph.D., 617-207-5509

[liz@synlogictx.com](mailto:liz@synlogictx.com)

or

#### **MEDIA CONTACT:**

Courtney Heath, 617-872-2462

[courtney@scientpr.com](mailto:courtney@scientpr.com)